Michael B. Cook

Michael B. Cook

Auto-generated profile, based on publicly available information

Michael B. Cook

National Cancer Institute, Bethesda, MD, United States

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
MCMichael B. Cook
Michael B. Cook
MGMichael Gamborg
Michael Gamborg
JAJulie Aarestrup
Julie Aarestrup
TSThorkild I.A. Sørensen
Thorkild I.A. Sørensen
JBJennifer L. Baker
Jennifer L. Baker
Background: Adult height has been positively associated with prostate cancer risk. However, the exposure window of importance is currently unknown and assessments of height during earlier growth periods are scarce. In addition, the association between birth weight and prostate cancer remains undetermined. We assessed these relationships in a cohort of the Copenhagen School Health Records Register (CSHRR). Methods: The CSHRR comprises 372,636 school children. For boys born between the 1930s and 1969, birth weight and annual childhood heights—measured between ages 7 and 13 years—were analyzed in relation to prostate cancer risk. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CI). Results: There were 125,211 males for analysis, 2,987 of who were subsequently diagnosed with prostate cancer during 2.57 million person-years of follow-up. Height z-score was significantly associated with prostate cancer risk at all ages (HRs, 1.13 to 1.14). Height at age 13 years was more important than height change (P = 0.024) and height at age 7 years (P = 0.024), when estimates from mutually adjusted models were compared. Adjustment of birth weight did not alter the estimates. Birth weight was not associated with prostate cancer risk. Conclusions: The association between childhood height and prostate cancer risk was driven by height at age 13 years. Impact: Our findings implicate late childhood, adolescence, and adulthood growth periods as containing the exposure window(s) of interest that underlies the association between height and prostate cancer. The causal factor may not be singular given the complexity of both human growth and carcinogenesis. Cancer Epidemiol Biomarkers Prev; 22(12); 2232–40. ©2013 AACR.

1 December 2018 in Journal of Global Oncology
Verified
Journal Article
Open access
CACaroline Andrews
Caroline Andrews
BFBrian Fortier
Brian Fortier
AHAmy Hayward
Amy Hayward
RLRuth Lederman
Ruth Lederman
LPLindsay Petersen
Lindsay Petersen
TRTimothy R. Rebbeck
Timothy R. Rebbeck
Purpose: Cancer of the prostate (CaP) is the leading cancer among men in sub-Saharan Africa (SSA). A substantial proportion of these men with CaP are diagnosed at late (usually incurable) stages, yet little is known about the etiology of CaP in SSA. Methods: We established the Men of African Descent and Carcinoma of the Prostate Network, which includes seven SSA centers partnering with five US centers to study the genetics and epidemiology of CaP in SSA. We developed common data elements and instruments, regulatory infrastructure, and biosample collection, processing, and shipping protocols. We tested this infrastructure by collecting epidemiologic, medical record, and genomic data from a total of 311 patients with CaP and 218 matched controls recruited at the seven SSA centers. We extracted genomic DNA from whole blood, buffy coat, or buccal swabs from 265 participants and shipped it to the Center for Inherited Disease Research (Baltimore, MD) and the Centre for Proteomics and Genomics Research (Cape Town, South Africa), where genotypes were generated using the UK Biobank Axiom Array. Results: We used common instruments for data collection and entered data into the shared database. Double-entered data from pilot participants showed a 95% to 98% concordance rate, suggesting that data can be collected, entered, and stored with a high degree of accuracy. Genotypes were obtained from 95% of tested DNA samples (100% from blood-derived DNA samples) with high concordance across laboratories. Conclusion: We provide approaches that can produce high-quality epidemiologic and genomic data in multicenter studies of cancer in SSA.

1 July 1996 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDF file
RER.J. Epstein
R.J. Epstein
SKS.A. Kelly
S.A. Kelly
MCM. Cook
M. Cook
ABA. Bateman
A. Bateman
IPI. Paddick
I. Paddick
PPP.M. Price
P.M. Price

1 May 2019 in Epidemiology
Verified
Journal Article
Open access
LPLauren E. Parlett
Lauren E. Parlett
DBDaniel C. Beachler
Daniel C. Beachler
SLStephan Lanes
Stephan Lanes
RHRobert N. Hoover
Robert N. Hoover
MCMichael B. Cook
Michael B. Cook
Background: Prostate cancer is a commonly studied outcome in administrative claims studies, but there is a dearth of validated case identifying algorithms. The long-term development of the disease increases the difficulty in separating prevalent from incident prostate cancer. The purpose of this validation study was to assess the accuracy of a claims algorithm to identify incident prostate cancer among men in commercial and Medicare Advantage US health plans. Methods: We identified prostate cancer in claims as a prostate cancer diagnosis within 28 days after a prostate biopsy and compared case ascertainment in the claims with the gold standard results from the Georgia Comprehensive Cancer Registry (GCCR). Results: We identified 74,008 men from a large health plan claims database for possible linkage with GCCR. Among the 382 prostate cancer cases identified in claims, 312 were also identified in the GCCR (positive predictive value [PPV] = 82%). Of the registry cases, 91% (95% confidence interval = 88, 94) were correctly identified in claims. Claims and registry diagnosis dates of prostate cancer matched exactly in 254/312 (81%) cases. Nearly half of the false-positive cases also had claims for prostate cancer treatment. Thirteen (43%) false-negative cases were classified as noncases by virtue of having a biopsy and diagnosis >28 days apart as required by the algorithm. Compared to matches, false-negative cases were older men with less aggressive prostate cancer. Conclusions: Our algorithm demonstrated a PPV of 82% with 92% sensitivity in ascertaining incident PC. Administrative health plan claims can be a valuable and accurate source to identify incident prostate cancer cases.

6 January 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JPJessica L. Petrick
Jessica L. Petrick
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
LLLinda M. Liao
Linda M. Liao
CAChristian C. Abnet
Christian C. Abnet
XWXiaolin Wu
Xiaolin Wu
MCMichael B. Cook
Michael B. Cook

2 January 2023 in Acta Oncologica
Verified
Journal Article
Open access
TRTrude Eid Robsahm
Trude Eid Robsahm
KTK. M. Tsuruda
K. M. Tsuruda
HHH. H. Hektoen
H. H. Hektoen
ASA. H. Storås
A. H. Storås
MCM. B. Cook
M. B. Cook
HLH. Langseth
H. Langseth
The Prostate Cancer Cohort Consortium (PC3) Working Group proposed a definition for aggressive prostate cancer (PC) for aetiologic epidemiologic research. We aimed to validate this definition as we...